TITLE

Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia

AUTHOR(S)
Kemp P M; Holmes C; Hoffmann S M A; Bolt L; Holmes R; Rowden J; Fleming J S
PUB. DATE
June 2003
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jun2003, Vol. 74 Issue 6, p715
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To compare the HMPAO SPECT cerebral perfusion patterns in early and late onset Alzheimer's disease. METHODS: Twenty patients with early onset disease (<65 years) and 44 patients with late onset disease (>65 years) were studied. All patients fulfilled NINCDS-ADRDA clinical criteria and had details of disease severity and length of history at the time of imaging. Technetium-99m HMPAO SPECT brain scans were acquired on a multi-detector gammacamera and analysed visually and with statistical parametric mapping (SPM99). RESULTS: Patients with early onset disease had significantly greater posterior cortical association area involvement whereas those with late onset disease had significantly greater medial temporal hypoperfusion. These findings were unchanged after controlling for disease severity and length of illness. DISCUSSION: These functional imaging findings of the differences between early and late onset Alzheimer's disease are supported by published findings that include histopathological and clinical evidence; namely late onset patients tend to present with the characteristic involvement of the medial temporal lobes producing marked memory loss whereas early onset patients present with predominant posterior cortical association area involvement. These age related findings should be borne in mind when clinically diagnosing, and interpreting functional brain imaging studies in, patients with suspected Alzheimer's disease.
ACCESSION #
10631456

 

Related Articles

  • Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease. Nunes, Marielza Andrade; Schöwe, Natalia Mendes; Monteiro-Silva, Karla Cristina; Baraldi-Tornisielo, Ticiana; Souza, Suzzanna Ingryd Gonçalves; Balthazar, Janaina; Albuquerque, Marilia Silva; Caetano, Ariadiny Lima; Viel, Tania Araujo; Buck, Hudson Sousa // PLoS ONE;11/25/2015, Vol. 10 Issue 11, p1 

    The use of lithium is well established in bipolar disorders and the benefits are being demonstrated in neurodegenerative disorders. Recently, our group showed that treatment with microdose lithium stabilized the cognitive deficits observed in Alzheimer’s disease (AD) patients. In order to...

  • Alzheimer's and prion diseases: PDK1 at the crossroads. Checler, Frédéric // Nature Medicine;Sep2013, Vol. 19 Issue 9, p1088 

    The article focuses on a study regarding the activation of phosphoinositide-dependent kinase-1 by cellular prion protein which in turn alters membrane associated transcatheter arterial chemoembolization (TACE) levels and thereby influencing both Alzheimer's and prion pathologies and also...

  • An In Vivo Evaluation of Cerebral Cortical Amyloid with [F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients. Wong, Dean; Moghekar, Abhay; Rigamonti, Daniele; Brašić, James; Rousset, Olivier; Willis, William; Buckley, Chris; Smith, Adrian; Gok, Beril; Sherwin, Paul; Grachev, Igor // Molecular Imaging & Biology;Apr2013, Vol. 15 Issue 2, p230 

    Purpose: The primary objectives of this study were to assess the safety of [F]flutemetamol injection and determine the level of association between the quantitative estimates of brain uptake of [F]flutemetamol and the quantitative immunohistochemical (IHC) estimates of amyloid levels in cerebral...

  • New drug discovery for Alzheimer's disease: Challenges and hopes. Sathyanarayana Rao, T. S.; Jagannatha Rao, K. // Indian Journal of Psychiatry;2009, Vol. 51 Issue 2, p79 

    The author reflects on the new drug discovery for Alzheimer's disease (AD). The author avers that the big extracellular bet-amyloid plaques and tau-containing intraneurofibrillary tangles describe AD as histopathologic view. The author believes that the discovery will improve the rate of health...

  • Evaluating Memory Wallets in Conversations With Persons With Dementia. Bourgeois, Michelle S. // Journal of Speech & Hearing Research;Dec92, Vol. 35 Issue 6, p1344 

    Provides information on a study which determined the effects of the memory wallet intervention among subjects with Alzheimer's disease. Method; Results; Discussion.

  • Mild forgetfulness may not mean Alzheimer's disease.  // San Diego Business Journal;05/10/99, Vol. 20 Issue 19, p18 

    Compares forgetfulness and Alzheimer's disease. Epidemiology of Alzheimer's disease; Treatment options for Alzheimer's disease.

  • Can estrogen keep you smart? Evidence from clinical studies. Sherwin, Barbara B. // Journal of Psychiatry & Neuroscience;Sep99, Vol. 24 Issue 4, p315 

    Examines the link between estrogen level and memory in women. Neurochemical effects of estrogen on the cholinergic system; Role of estrogen in the maintenance of verbal memory; Importance of estrogen replacement therapy (ERT) in the prevention of age-related deterioration of memory; Use of ERT...

  • Remote Odor Memory in Alzheimer's Disease: Deficits as Measured by Familiarity. Niccoli-Waller, Caprice A.; Harvey, Jodi; Nordin, Steven; Murphy, Claire // Journal of Adult Development;Apr1999, Vol. 6 Issue 2, p131 

    Deficit in olfaction and remote nonolfactory memory in Alzheimer's disease (AD) motivated the present study of remote memory for odors and faces, operationally defined as rated familiarity, in patients with AD and controls. Uncommon engineering symbols were rated for familiarity to ensure task...

  • The Memory Impairment Screen more accurately screened for Alzheimer disease than the 3-word memory test in older adults. Molloy, D. W. // ACP Journal Club;Jan/Feb2003, Vol. 138 Issue 1, p25 

    Focuses on a study which investigated the accuracy of the Memory Impairment Screen compared with the conventional 3-word memory test for screening for Alzheimer disease. Assessment of the clinical characteristics of patients; Description of tests and diagnostic standards; Outcome measures.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics